Approval · Notice of Compliance 261 · 2003
COLESTID TABLETS: Notice of Compliance 261
Issued September 15, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 261
- Date
- September 15, 2003
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Oral antihypercholesterolemic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COLESTID TABLETS | 02132680 | Marketed |
| COLESTID GRANULES | 00642975 | Cancelled Post Market |
| COLESTID ORANGE GRANULES | 02132699 | Cancelled Post Market |
Medicinal ingredients
- COLESTIPOL HCL 1 G per TAB
- COLESTIPOL HCL 5 G per PCK
- COLESTIPOL HCL 7.5 G per PCK